Investors
MD Medical Group Today
Investment Case
01
02
03
04
05
Revenue
Rub33.1 bn
for 2024
EBITDA
Rub10.7 bn
for 2024
Profit
up to 100%
may be allocated to dividends
Cash
Rub6 bn
as at 31.12.2024
Key Financials
| 2024 | 2023 | 2022 | 2021 | 2020 | |
| Revenue, Rub mln | 33,122 | 27,631 | 25,222 | 25,220 | 19,133 |
| EBITDA, Rub mln | 10,681 | 9,218 | 7,924 | 8,276 | 6,008 |
| EBITDA margin, % | 32 | 33 | 31 | 33 | 31 |
| Net profit, Rub mln | 9,825* | 7,823 | 6,005* | 6,143 | 4,333 |
| Net margin, % | 30 | 28 | 24 | 24 | 23 |
| CAPEX, Rub mln | 2,273 | 3,580 | 1,169 | 3,790 | 3,904 |
| Net debt/EBITDA | -0.4x | -1.0x | -0.5x | 0.2x | 0.5x |
*Adjusted for non-cash items
Annual reports
MD Medical Group Annual Report
PDF
2024 г.
MD Medical Group Annual Report
PDF
2023
MD Medical Group Annual Report
PDF
2022
Share capital structure
Financial and Operating Results
2024 Financial Results
PDF
0.3 Mb
4Q 2024 Operating Results
PDF
0.3 Mb
Company's Databook
XLS
0.3 Mb
Corporate Governance
MD Medical adheres to the highest standards of corporate governance. The Company has an effective system of corporate governance and internal control of financial and economic activities that complies with Russian legislation, the rules of the Moscow Exchange, and the best international practices.
Continuous improvement of the corporate governance system is one of the main long-term strategic priorities of the Company.
More
Events Calendar
April
28
Q1 2025 Operating results
July
31
Q2 2025 Operating results
